Venetoclax had little effect on the viability of the NPM mutant OCI-AML-3 cell line (resistance to Bcl-2 inhibitors has been seen previously in this cell line; data not shown); hence, there was no notable difference between single-agent idasanutlin (relative/absolute IC50, 164/147 nM) and the combination treatment for this cell line (relative/absolute IC50, 142/133 nM). Here, BCL2 is linked to acute myeloid leukemia.